Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04217330
Other study ID # 55803
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 1, 2021
Est. completion date August 2025

Study information

Verified date October 2023
Source Monash University
Contact Anne Holland
Phone +61 3 99030214
Email a.holland@alfred.org.au
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

People with chronic obstructive pulmonary disease (COPD) experience distressing breathlessness and high health care utilisation. There is compelling evidence that pulmonary rehabilitation improves symptoms and reduces hospitalisation, but is delivered to <10% of patients who would benefit. The investigators developed a low cost model of pulmonary rehabilitation that can be delivered entirely at home. The HomeBase model had equivalent outcomes to centre-based pulmonary rehabilitation in a phase II efficacy trial, with higher completion rates. The investigators hypothesise that a patient centred model offering a choice between home or centre-based pulmonary rehabilitation may increase program completion rates, with improved outcomes for patients and the health system. This is a cluster randomised implementation trial investigating whether offering a choice of home or centre-based pulmonary rehabilitation can reduce hospitalisation, improve pulmonary rehabilitation completion and enhance patient outcomes in people with COPD. 14 pulmonary rehabilitation programs located across Australia will each recruit 35 people with COPD. Intervention centres: People with COPD will be offered the choice of centre-based pulmonary rehabilitation or the HomeBase model. Comparison centres: Only the existing centre-based model will be offered. The primary outcome is all cause, non-elective hospitalisation at 12 months. Other outcomes are symptoms, exercise capacity and quality of life at 8 weeks and 12 months; and health care costs at 12 months for full economic evaluation.


Recruitment information / eligibility

Status Recruiting
Enrollment 490
Est. completion date August 2025
Est. primary completion date August 2024
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion criteria for pulmonary rehabilitation programs: • Outpatient pulmonary rehabilitation programs that admit at least 50 people with COPD each year. Inclusion criteria for participants: - Diagnosis of COPD confirmed on spirometry - Able to read, write and speak English - Able to provide informed consent. Exclusion Criteria: - Attended pulmonary rehabilitation within 1 year - Comorbidities which preclude exercise training.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Choice of home-based or centre-based pulmonary rehabilitation
Participants will be offered the choice of HomeBase, a home-based pulmonary rehabilitation program, or the traditional centre-based pulmonary rehabilitation program.
Centre-based pulmonary rehabilitation
Participants will be offered a traditional centre-based pulmonary rehabilitation program

Locations

Country Name City State
Australia Central Adelaide Local Health Network Adelaide South Australia
Australia Southern Adelaide Local Health Network Adelaide South Australia
Australia Prince Charles Hospital Brisbane Queensland
Australia Top End Health Service Darwin Northern Territory
Australia Peninsula Health Melbourne Victoria
Australia St John of God Frankston Rehabilitation Melbourne Victoria
Australia Western Health Melbourne Victoria
Australia Mount Druitt Hospital Sydney New South Wales
Australia Prince of Wales Hospital Sydney New South Wales
Australia Royal Prince Alfred Hospital Sydney New South Wales
Australia Westmead Hospital Sydney New South Wales

Sponsors (6)

Lead Sponsor Collaborator
Monash University Institute for Breathing and Sleep, Australia, La Trobe University, Lung Foundation Australia, Thoracic Society of Australia and New Zealand, University of Melbourne

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary All cause, non-elective hospitalisation The number of participants hospitalised at least once will be compared between groups 12 months after completing pulmonary rehabilitation
Secondary Change in 6-minute walk distance Distance walked in 6 minutes End of rehabilitation and 12 months later
Secondary Change in chronic respiratory disease questionnaire total and domain scores Disease-specific health-related quality of life measure; scores range 1-7, higher scores indicate better health-related quality of life End of rehabilitation and 12 months later
Secondary EQ-5D-5L Generic health-related quality of life measure to inform economic analysis; 5 dimensions each scored 1-5 with lower values indicating better health-related quality of life End of rehabilitation and 12 months later
Secondary Change in dyspnoea-12 Global measure of breathlessness; total scores range from 0 to 36, with higher scores corresponding to greater severity of dyspnoea End of rehabilitation and 12 months later
Secondary Change in objectively measured physical activity Objective measure of physical activity using the actigraph End of rehabilitation and 12 months later
Secondary Health care costs Health care costs in Australian dollars will be calculated using health care utilisation data including hospitalisation, primary care visits and medication use 12 months following pulmonary rehabilitation completion
Secondary Program completion The number of participants who complete their allocated rehabilitation program (attend at least 70% of planned sessions). End of rehabilitation
See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03089515 - Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy